Evidence map›Paper›PMID 40590912›Full record

ArticleAnnals of hematology2025

Sickle cell β-thalassemia diagnosed at age 40: a case report.

Christos G Nikolaidis, Despoina Gyriki, Dimitrios G Gogos, Elisavet Stavropoulou

Abstract readCase Reports
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christos G NikolaidisDepartment of Internal Medicine, Vostaneio-General Hospital of Mytilene, Mytilene, Greece.ORCID http://orcid.org/0000-0001-6271-5595
Despoina GyrikiDepartment of Internal Medicine, Vostaneio-General Hospital of Mytilene, Mytilene, Greece.ORCID http://orcid.org/0009-0008-5439-2149
Dimitrios G GogosDepartment of Hematology, Vostaneio-General Hospital of Mytilene, Mytilene, Greece.
Elisavet StavropoulouMaster Program in "Food, Nutrition and Microbiome", Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. elisabeth.stavropoulou@gmail.com.ORCID http://orcid.org/0000-0002-8299-9035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary hemoglobinopathies, including sickle cell disease and thalassemias, affect thousands of newborns annually, predominantly in low-and middle-income countries. Sickle cell β-thalassemia (HbSβ-thal), a form of compound heterozygosity involving β-thalassemia, presents with a wide range of clinical severity depending on the specific mutations. However, the clinical manifestations remain poorly defined. We report the case of a 40-year-old Greek female patient presenting with symptomatic sickle cell β-thalassemia, symptoms of tissue hypoperfusion caused by markedly low hemoglobin levels and notably, bone marrow necrosis. Remarkably, her condition remained undiagnosed until her admission to the emergency department. This case underscores the importance of maintaining a high index of clinical suspicion for the late-onset diagnosis of HbSβ-thal, particularly considering its increased prevalence in certain countries. The successful treatment strategy employed in this case highlights the critical role of individualized care in managing the severe and multifaceted symptoms associated with this genetic disorder, offering valuable insights for clinicians worldwide.

Indexed as

Anemia, Sickle Cellbeta-ThalassemiaAdultFemaleHumansAgeCase reportHbSβ-thalHemoglobinopathyLate-onsetSickle cell β-thalassemia

Identifiers

PMID40590912
PMCPMC12432073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.